HRP20201785T1 - Multivalentni i multispecifični fuzijski proteini koji vežu dr5 - Google Patents
Multivalentni i multispecifični fuzijski proteini koji vežu dr5 Download PDFInfo
- Publication number
- HRP20201785T1 HRP20201785T1 HRP20201785TT HRP20201785T HRP20201785T1 HR P20201785 T1 HRP20201785 T1 HR P20201785T1 HR P20201785T T HRP20201785T T HR P20201785TT HR P20201785 T HRP20201785 T HR P20201785T HR P20201785 T1 HRP20201785 T1 HR P20201785T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- isolated polypeptide
- dr5bd
- polypeptide according
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193309P | 2015-07-16 | 2015-07-16 | |
| PCT/US2016/042862 WO2017011837A2 (en) | 2015-07-16 | 2016-07-18 | Multivalent and multispecific dr5-binding fusion proteins |
| EP16825315.1A EP3322734B1 (en) | 2015-07-16 | 2016-07-18 | Multivalent and multispecific dr5-binding fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201785T1 true HRP20201785T1 (hr) | 2021-01-22 |
Family
ID=57757772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201785TT HRP20201785T1 (hr) | 2015-07-16 | 2016-07-18 | Multivalentni i multispecifični fuzijski proteini koji vežu dr5 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10308720B2 (enExample) |
| EP (2) | EP3322734B1 (enExample) |
| JP (4) | JP6807606B2 (enExample) |
| KR (2) | KR102760380B1 (enExample) |
| CN (2) | CN114106178A (enExample) |
| AU (3) | AU2016291701B2 (enExample) |
| CA (2) | CA3288875A1 (enExample) |
| CY (1) | CY1123615T1 (enExample) |
| DK (1) | DK3322734T3 (enExample) |
| ES (1) | ES2833773T3 (enExample) |
| HR (1) | HRP20201785T1 (enExample) |
| HU (1) | HUE051896T2 (enExample) |
| IL (3) | IL307994A (enExample) |
| LT (1) | LT3322734T (enExample) |
| MX (2) | MX2018000523A (enExample) |
| NZ (1) | NZ777930A (enExample) |
| PL (1) | PL3322734T3 (enExample) |
| PT (1) | PT3322734T (enExample) |
| RS (1) | RS61062B1 (enExample) |
| RU (2) | RU2748620C2 (enExample) |
| SG (1) | SG10201912410TA (enExample) |
| SI (1) | SI3322734T1 (enExample) |
| SM (1) | SMT202100066T1 (enExample) |
| WO (1) | WO2017011837A2 (enExample) |
| ZA (1) | ZA201800238B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN111819198A (zh) * | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| WO2020047705A1 (zh) * | 2018-09-03 | 2020-03-12 | 安菲尼生命科技有限公司 | Dr5单域抗体及其用途 |
| GB201903767D0 (en) * | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| BR112022006364A2 (pt) * | 2019-10-01 | 2022-06-28 | Epsilogen Ltd | Anticorpo híbrido |
| CN115698088A (zh) * | 2020-06-30 | 2023-02-03 | 和铂医药(上海)有限责任公司 | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 |
| WO2022002033A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 具有H2L2与HCAb结构的结合蛋白 |
| CN115667316A (zh) * | 2020-06-30 | 2023-01-31 | 和铂医药(上海)有限责任公司 | Fab-HCAb结构的结合蛋白 |
| IL305265A (en) * | 2021-02-19 | 2023-10-01 | Inhibrx Inc | Preparations of DR5-binding polypeptides |
| CN119365489A (zh) * | 2022-04-08 | 2025-01-24 | 印希比生物科学有限公司 | Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法 |
| CA3254393A1 (en) * | 2022-05-23 | 2023-11-30 | Inhibrx Biosciences, Inc. | DR5 AGONIST AND IAP ANTAGONIST POLYTHERAPY |
| JP2025534309A (ja) | 2022-09-28 | 2025-10-15 | ヴァリンク セラピューティクス リミテッド | 多価タンパク質およびスクリーニング法 |
| KR20260032566A (ko) * | 2023-06-29 | 2026-03-09 | 오디세이 테라퓨틱스, 인코포레이티드 | 항-trailr2 항원-결합 단백질 및 그의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69131017T2 (de) | 1990-12-20 | 1999-07-15 | Ixsys, Inc., San Diego, Calif. | Optimierung von bindenden proteinen |
| US20020147140A1 (en) * | 2000-01-31 | 2002-10-10 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| EA200701211A1 (ru) | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
| MX2007010349A (es) | 2005-02-24 | 2008-04-09 | Cemines Inc | Composiciones y metodos para clasificar muestras biologicas. |
| CA2619725C (en) | 2005-08-18 | 2016-06-07 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
| TW200804425A (en) | 2005-12-06 | 2008-01-16 | Domantis Ltd | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
| DK1987178T3 (en) | 2006-02-20 | 2015-04-20 | Phylogica Ltd | Process for the construction and screening of peptide structure libraries |
| JP2008133206A (ja) | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
| SG186017A1 (en) | 2007-11-30 | 2012-12-28 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| HUE042053T2 (hu) | 2008-06-05 | 2019-06-28 | Ablynx Nv | Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére |
| EP2328929A2 (en) * | 2008-09-10 | 2011-06-08 | Bac Ip B.V. | Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases |
| US9096659B2 (en) | 2009-03-18 | 2015-08-04 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa |
| US20100281003A1 (en) | 2009-04-02 | 2010-11-04 | New York University | System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions |
| CN101717775B (zh) * | 2009-11-13 | 2012-01-04 | 厦门大学 | 抗人死亡受体5的单链抗体基因 |
| HRP20251657T1 (hr) | 2009-12-14 | 2026-02-13 | Ablynx N.V. | Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba |
| US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| WO2011134060A1 (en) | 2010-04-27 | 2011-11-03 | National Research Council Of Canada | Anti-icam-1 single domain antibody and uses thereof |
| NZ607473A (en) | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| US9771416B2 (en) | 2010-10-25 | 2017-09-26 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
| KR20130133212A (ko) | 2010-12-23 | 2013-12-06 | 인터셀 오스트리아 아게 | 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도 |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| JP6170940B2 (ja) | 2011-12-20 | 2017-07-26 | アダエラータ、リミテッド パートナーシップＡｄａｅｒａｔａ， Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ | Ｐｃｓｋ９の阻害剤としての単一ドメイン抗体 |
| MX2014010495A (es) | 2012-03-02 | 2014-11-14 | Ablynx Nv | Polipeptidos que enlazan a pcrv. |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| EP2684896A1 (en) * | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| US20140161796A1 (en) | 2012-09-13 | 2014-06-12 | Andreas Loew | Single chain proteins with c-terminal modifications |
| JP2015535005A (ja) | 2012-11-06 | 2015-12-07 | メディミューン，エルエルシー | 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療 |
| CN102924600B (zh) * | 2012-11-14 | 2013-10-30 | 河南大学 | 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用 |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| US9862777B2 (en) | 2013-05-28 | 2018-01-09 | Vib Vzw | Single domain antibodies against SOD1 and their use in medicine |
| CA2936053A1 (en) * | 2014-01-10 | 2015-07-16 | Teikyo Heisei University | Recombinant obligate anaerobic gram-positive bacteria |
-
2016
- 2016-07-18 CN CN202111039963.9A patent/CN114106178A/zh active Pending
- 2016-07-18 JP JP2018501345A patent/JP6807606B2/ja active Active
- 2016-07-18 IL IL307994A patent/IL307994A/en unknown
- 2016-07-18 RS RS20201315A patent/RS61062B1/sr unknown
- 2016-07-18 SG SG10201912410TA patent/SG10201912410TA/en unknown
- 2016-07-18 NZ NZ777930A patent/NZ777930A/en unknown
- 2016-07-18 PL PL16825315T patent/PL3322734T3/pl unknown
- 2016-07-18 DK DK16825315.1T patent/DK3322734T3/da active
- 2016-07-18 AU AU2016291701A patent/AU2016291701B2/en active Active
- 2016-07-18 KR KR1020187000975A patent/KR102760380B1/ko active Active
- 2016-07-18 EP EP16825315.1A patent/EP3322734B1/en active Active
- 2016-07-18 CA CA3288875A patent/CA3288875A1/en active Pending
- 2016-07-18 LT LTEP16825315.1T patent/LT3322734T/lt unknown
- 2016-07-18 HU HUE16825315A patent/HUE051896T2/hu unknown
- 2016-07-18 MX MX2018000523A patent/MX2018000523A/es unknown
- 2016-07-18 IL IL292037A patent/IL292037A/en unknown
- 2016-07-18 RU RU2018102803A patent/RU2748620C2/ru active
- 2016-07-18 HR HRP20201785TT patent/HRP20201785T1/hr unknown
- 2016-07-18 CA CA2991634A patent/CA2991634C/en active Active
- 2016-07-18 EP EP20189995.2A patent/EP3798232A1/en active Pending
- 2016-07-18 US US15/213,296 patent/US10308720B2/en active Active
- 2016-07-18 ES ES16825315T patent/ES2833773T3/es active Active
- 2016-07-18 SM SM20210066T patent/SMT202100066T1/it unknown
- 2016-07-18 SI SI201631005T patent/SI3322734T1/sl unknown
- 2016-07-18 KR KR1020257002277A patent/KR20250017305A/ko active Pending
- 2016-07-18 PT PT168253151T patent/PT3322734T/pt unknown
- 2016-07-18 WO PCT/US2016/042862 patent/WO2017011837A2/en not_active Ceased
- 2016-07-18 RU RU2021111382A patent/RU2021111382A/ru unknown
- 2016-07-18 CN CN201680041274.2A patent/CN107922491B/zh active Active
-
2018
- 2018-01-07 IL IL256772A patent/IL256772B/en unknown
- 2018-01-12 MX MX2023002379A patent/MX2023002379A/es unknown
- 2018-01-12 ZA ZA2018/00238A patent/ZA201800238B/en unknown
-
2019
- 2019-04-18 US US16/387,754 patent/US11117973B2/en active Active
-
2020
- 2020-11-16 CY CY20201101085T patent/CY1123615T1/el unknown
- 2020-11-26 JP JP2020196358A patent/JP7244938B2/ja active Active
-
2021
- 2021-08-05 US US17/394,900 patent/US11976126B2/en active Active
-
2022
- 2022-11-30 JP JP2022191038A patent/JP2023022214A/ja active Pending
- 2022-12-21 AU AU2022291498A patent/AU2022291498A1/en not_active Abandoned
-
2024
- 2024-04-04 US US18/626,699 patent/US20240376220A1/en active Pending
-
2025
- 2025-03-03 JP JP2025032594A patent/JP2025084923A/ja active Pending
-
2026
- 2026-01-16 AU AU2026200317A patent/AU2026200317A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| IL259927B1 (en) | Humanized antibodies against cd73 | |
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| HRP20240767T1 (hr) | Cd3 vezujuća antitijela | |
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20200679T1 (hr) | Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji | |
| JP2018523493A5 (enExample) | ||
| HRP20240774T1 (hr) | Anti-il-33 antitijela i njihove upotrebe | |
| JP2016536322A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
| HRP20251127T1 (hr) | Humanizirana ili himerična cd3 protutijela | |
| JP2018520650A5 (enExample) | ||
| MY186351A (en) | Multispecific antibodies | |
| HRP20230528T1 (hr) | Bispecifične molekule t stanica aktivirane proteazom | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование |